ConductScience.org, home

Paper41553253

Clinical Trial: Efficacy and Safety of Velusetrag in Chronic Intestinal Pseudo-Obstruction: A Randomized, Phase 2, Placebo-Controlled, Crossover, Multiple (n = 1), Proof-of-Concept Study.

Malagelada C and 9 others. Neurogastroenterol Motil, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Clinical Trial: Efficacy and Safety of Velusetrag in Chronic Intestinal Pseudo-Obstruction: A Randomized, Phase 2, Placebo-Controlled, Crossover, Multiple (n = 1), Proof-of-Concept Study. Papers, record 41553253. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41553253

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical Trial: Efficacy and Safety of Velusetrag in Chronic Intestinal Pseudo-Obstruction: A Randomized, Phase 2, Placebo-Controlled, Crossover, Multiple (n = 1), Proof-of-Concept Study.
PubMed
Journal
Neurogastroenterol Motil
PubMed
Year
2026
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Multicenter Study
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-26
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Malagelada CCarolinahttps://orcid.org/0000-0001-7097-1492
2De Giorgio RRobertohttps://orcid.org/0000-0003-0867-5873
3Cogliandro RFRosanna Francescahttps://orcid.org/0009-0006-1258-0569
4Alcalá-González LLuishttps://orcid.org/0000-0003-3247-1539
5Costanzini AAnnahttps://orcid.org/0000-0002-8644-1135
6Scuderi VValeria
7Manzoni SSarahttps://orcid.org/0009-0009-1119-5986
8Pasquali EElena
9Tack JJanhttps://orcid.org/0000-0002-3206-6704
10Stanghellini VVincenzohttps://orcid.org/0000-0003-0559-4875

Source PubMed

Download CSV of authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Intestinal Pseudo-ObstructionMajor topic
Serotonin 5-HT4 Receptor AgonistsMajor topic
Humans
Male
Middle Aged
Female
Double-Blind Method
Cross-Over Studies
Adult
Aged
Treatment Outcome
Proof of Concept Study
Young Adult
Aged, 80 and over
Chronic Disease
Adolescent
Gastrointestinal Motility
Benzamides
Thiazoles

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Alfasigma S.p.A.PubMed
United European GastroenterologyPubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT05724069Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).Derived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129570554Paediatric Intestinal Pseudo-obstruction: Evidence and Consensus-based Recommendations From an ESPGHAN-Led Expert Group.J Pediatr Gastroenterol Nutr2018https://conductscience.org/library/papers/29570554PubMed
215084181Intestinal transplantation for chronic intestinal pseudo-obstruction in adult patients.Am J Transplant2004https://conductscience.org/library/papers/15084181PubMed
319367271Long-term outcome of chronic intestinal pseudo-obstruction adult patients requiring home parenteral nutrition.Am J Gastroenterol2009https://conductscience.org/library/papers/19367271PubMed
421039672
Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study.
Aliment Pharmacol Ther2010https://conductscience.org/library/papers/21039672PubMed
541209870Hydrogen-Positive Small Intestinal Bacterial Overgrowth (SIBO) in Japanese Patients With Chronic Intestinal Pseudo-Obstruction (CIPO): A Cross-Sectional Study.Cureus2025https://conductscience.org/library/papers/41209870PubMed
638562545Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase II-a exploratory trial.Biosci Microbiota Food Health2024https://conductscience.org/library/papers/38562545PubMed
722959244Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.Bioorg Med Chem Lett2012https://conductscience.org/library/papers/22959244PubMed
836939480Pharmacological and nutritional therapy of children and adults with chronic intestinal pseudo-obstruction.Expert Rev Gastroenterol Hepatol2023https://conductscience.org/library/papers/36939480PubMed
934946150Chronic Intestinal Pseudo-Obstruction: Is There a Connection with Gut Microbiota?Microorganisms2021https://conductscience.org/library/papers/34946150PubMed
1019308797Clinical features and long-term survival in chronic intestinal pseudo-obstruction and enteric dysmotility.Scand J Gastroenterol2009https://conductscience.org/library/papers/19308797PubMed
1127683196Chronic intestinal pseudo-obstruction in children and adults: diagnosis and therapeutic options.Neurogastroenterol Motil2017https://conductscience.org/library/papers/27683196PubMed
1222356640Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.Aliment Pharmacol Ther2012https://conductscience.org/library/papers/22356640PubMed
133817584Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings.Gut1987https://conductscience.org/library/papers/3817584PubMed
1418408918The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.Naunyn Schmiedebergs Arch Pharmacol2008https://conductscience.org/library/papers/18408918PubMed
1515880314Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study.Clin Gastroenterol Hepatol2005https://conductscience.org/library/papers/15880314PubMed
1641553253Clinical Trial: Efficacy and Safety of Velusetrag in Chronic Intestinal Pseudo-Obstruction: A Randomized, Phase 2, Placebo-Controlled, Crossover, Multiple (n = 1), Proof-of-Concept Study.Neurogastroenterol Motil2026https://conductscience.org/library/papers/41553253PubMed
1729180358Nonclinical Cardiovascular Studies of Prucalopride, a Highly Selective 5-Hydroxytryptamine 4 Receptor Agonist.J Pharmacol Exp Ther2018https://conductscience.org/library/papers/29180358PubMed
1823797870Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets.Nat Rev Gastroenterol Hepatol2013https://conductscience.org/library/papers/23797870PubMed
192022163Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility.Dig Dis Sci1991https://conductscience.org/library/papers/2022163PubMed
2015932370Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth.Aliment Pharmacol Ther2005https://conductscience.org/library/papers/15932370PubMed

See all 37 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
41553253Clinical Trial: Efficacy and Safety of Velusetrag in Chronic Intestinal Pseudo-Obstruction: A Randomized, Phase 2, Placebo-Controlled, Crossover, Multiple (n = 1), Proof-of-Concept Study.Neurogastroenterol Motil2026https://conductscience.org/library/papers/41553253

Source PubMed

Download CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
VELUSETRAGCHEMBL2087337Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2087337

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41553253

GET https://conductscience.org/api/papers/v1/41553253/references?page=2